A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/02/2006	WO2006115273A1 Method for treating body fluid
11/02/2006	WO2006115247A1 HIGHLY SELECTIVE Rho-KINASE INHIBITOR
11/02/2006	WO2006115245A1 4-ethynylisoquinoline derivative and pharmaceutical preparation comprising the same
11/02/2006	WO2006115244A1 4-bromoisoquinoline derivative and pharmaceutical preparation comprising the same
11/02/2006	WO2006115238A1 Gastrointestinal motor activation regulator
11/02/2006	WO2006115221A1 Phthalazinone derivative and pharmaceutical comprising the same
11/02/2006	WO2006115193A1 Remedy for xanthoma
11/02/2006	WO2006115188A1 Heterocyclic compound
11/02/2006	WO2006115187A1 Pharmaceutical for prevention or treatment of bone metabolic disease
11/02/2006	WO2006115185A1 Therapeutic agent for corneal/conjunctival disorder
11/02/2006	WO2006115168A1 N-substituted phenylacetamide derivative and pharmaceutical composition comprising the same
11/02/2006	WO2006115154A1 Crystal polymorphism of 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid hydrochloride
11/02/2006	WO2006115140A1 Preventive or remedy for bowel disease
11/02/2006	WO2006115137A1 2-aminobenzimidazole derivative and use of the same for medical purposes
11/02/2006	WO2006115136A1 Allergy-suppressive composition, allergy-suppressive food and allergy-suppressive agent
11/02/2006	WO2006115135A1 Therapeutic agent for irritable bowel syndrome
11/02/2006	WO2006115134A1 Novel benzofuran derivative, pharmaceutical composition comprising the same, and use of the derivative or composition
11/02/2006	WO2006115130A1 Calcium bis[(2s)-3-[3-[(2s)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy]phenyl]-2-isopropoxypropionate] and intermediate thereof
11/02/2006	WO2006115123A1 Virus-inactivating agent
11/02/2006	WO2006115115A1 Combined pharmaceutical preparation for treatment of type 2 diabetes
11/02/2006	WO2006115067A1 Peritoneal dialysis fluid
11/02/2006	WO2006115057A1 Artificial cerebrospinal fluid
11/02/2006	WO2006114868A1 Medicinal preparation for percutaneous absorption
11/02/2006	WO2006114709A1 Pharmaceutical compositions of antiretrovirals
11/02/2006	WO2006114707A1 Amino acid derivatives
11/02/2006	WO2006114706A1 Triazole derivatives as vasopressin antagonists
11/02/2006	WO2006114703A2 Method of administration of (1s,s2) -1- (4 -hydroxyphenyl) -2- (4-hydr0xy-4-phenylpiperidin-1-yl) -1- propano (traxoprodil)
11/02/2006	WO2006114702A2 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
11/02/2006	WO2006114666A1 SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
11/02/2006	WO2006114630A1 Compositions for intestinal conditions
11/02/2006	WO2006114606A1 Fused thiazole derivatives as kinase inhibitors
11/02/2006	WO2006114604A2 Water-soluble films comprising nicotine
11/02/2006	WO2006114520A2 Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
11/02/2006	WO2006114467A1 Use of hydroxytyrosol in the prevention and treatment of cerebral ischemic stroke
11/02/2006	WO2006114443A1 Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
11/02/2006	WO2006114402A1 Substituted octahydroisoindoles as antagonists of melanin concentrating hormone receptor 1 (mch1r)
11/02/2006	WO2006114400A1 Novel oxadiazole derivatives and their medical use
11/02/2006	WO2006114379A1 Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
11/02/2006	WO2006114372A1 Acetyl l-carnitine for preventing painful peripheral diabetic neuropathy
11/02/2006	WO2006114371A1 Novel compounds for treating inflammatory diseases
11/02/2006	WO2006114336A1 Fluorinated 3'-deoxythymidine derivatives, a method for their preparation and their use
11/02/2006	WO2006114333A1 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
11/02/2006	WO2006114313A1 Pyrazole compounds as prostaglandin receptors ligands
11/02/2006	WO2006114277A2 Dosage form with improved release of cefuroximaxetil
11/02/2006	WO2006114274A1 Oxazole and thiazole compounds and their use in the treatment of pge2 mediated disorders
11/02/2006	WO2006114272A1 FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS
11/02/2006	WO2006114264A1 Acetylene derivatives
11/02/2006	WO2006114263A1 Imidazo [1, 2-a] pyridine derivatives useful as peptide deformylase (pdf) inhibitors
11/02/2006	WO2006114262A1 Acetylene derivatives
11/02/2006	WO2006114261A1 Imidazo(1,2-a)pyridine derivatives useful as peptide deformylase (pdf) inhibitors
11/02/2006	WO2006114190A1 Novel specific caspase-10 inhibitors
11/02/2006	WO2006114180A1 Novel aza- heterocycles serving as kinase inhibitors
11/02/2006	WO2006114115A1 Combination of antibodies and glucocorticoids for treating cancer
11/02/2006	WO2006114093A1 Pro-drugs of n-thiazol-2yl-benzamide derivatives
11/02/2006	WO2006114065A2 Use of compounds to inhibit neoplasia
11/02/2006	WO2006114064A2 Use of compounds to enhance processivity of telomerase
11/02/2006	WO2006114061A1 A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vaginal
11/02/2006	WO2006114042A1 Application of levo-ornidazole in preparation of anti-anaerobic bacteria infection medicine
11/02/2006	WO2006114040A1 Preparation of multinuclear ferric-saccharidic complexes
11/02/2006	WO2006114001A1 Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
11/02/2006	WO2006113993A1 MATRIX METALLOPROTEINASE INHIBITORS OF TGFß -INDUCED SUBCAPSULAR CATARACT FORMATION
11/02/2006	WO2006113981A2 Process to obtain dibenzylbutyrolactonic, tetrahydrofuranic lignans and their synthetic and semi-synthetic derivatives, their analgesic and anti-inflammatory activities, topical and/or systemic formulations containing said lignans and their respective therapeutic method
11/02/2006	WO2006093823A9 2- [ isoquinolin-s - carbonyl ) amino] -propionic acid derivatives as inhibitors of factors xi and ix for the treatment of thrombosis
11/02/2006	WO2006092032A3 PHARMACEUTICAL COMPOSITIONS CONTAINING 1-METHYL-3,6,7,8-TETRAHYDROPIRAZOLO[3,4-b]PIRROLO[4,3-d]PYRIDINE-6,8-DIONE DERIVATIVES, USE, AND PROCESS FOR PREPARING THEM
11/02/2006	WO2006091428A3 Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity
11/02/2006	WO2006090142A9 l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST
11/02/2006	WO2006089664A3 Heterocyclylamide-substituted imidazoles
11/02/2006	WO2006089150A3 Antiangiogenic agents with aldesleukin
11/02/2006	WO2006088921A3 Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
11/02/2006	WO2006088919A3 Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
11/02/2006	WO2006088837A3 Heterocyclic substituted piperazines with cxcr3 antagonist activity
11/02/2006	WO2006088836A3 Piperazine-piperidines with cxcr3 antagonist activity
11/02/2006	WO2006087752A3 Cationic lipids for the transfection of nucleic acids
11/02/2006	WO2006087629A3 Rapidly disintegrating composition of olanzapine
11/02/2006	WO2006087077A3 Hsp90-inhibiting triazole derivatives
11/02/2006	WO2006086727A3 Treating diabetes with glucagon-like peptide-1 secretagogues
11/02/2006	WO2006086500A3 Compositions and methods for treating vascular, autoimmune and inflammatory diseases
11/02/2006	WO2006086498A3 Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
11/02/2006	WO2006085337B1 Parenteral combination therpy for infective conditions with drug resistant bacterium
11/02/2006	WO2006084854A3 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
11/02/2006	WO2006084474A3 A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
11/02/2006	WO2006084153A3 Methods and materials with trans-clomiphene for the treatment of male infertility
11/02/2006	WO2006079559A3 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
11/02/2006	WO2006077012A3 USE OF LXR LIGANDS FOR THE MODULATION OF DENDRITIC CELLS (DCs)
11/02/2006	WO2006076663A3 Kits and improved compositions for treating lower urinary tract
11/02/2006	WO2006075330A3 Methods and pharmaceutical compositions useful for treating psoriasis
11/02/2006	WO2006072953A3 Rigidified compounds for modulating heparanase activity
11/02/2006	WO2006072921A3 Sweetener composition of stevia extract and maltol and processes of preparation thereof
11/02/2006	WO2006072809A3 Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions
11/02/2006	WO2006069808A3 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
11/02/2006	WO2006067224A3 Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
11/02/2006	WO2006063408A8 Compositions and methods for treating cardiovascular disorders
11/02/2006	WO2006061392A3 Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives
11/02/2006	WO2006061380A3 SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION
11/02/2006	WO2006059344B1 Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection
11/02/2006	WO2006059149A8 Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
11/02/2006	WO2006053067A3 Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
11/02/2006	WO2006047544A3 Compositions and methods for treating alzheimer’s disease and related disorders and promoting a healthy nervous system
11/02/2006	WO2006047237A3 Heterocyclic indanone potentiators of metabotropic glutamate receptors
11/02/2006	WO2006033007A3 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

1 ... 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 ... 7860